Journal of Clinical Medicine (Apr 2015)

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

  • Ramya Kollipara,
  • Erfon Ekhlassi,
  • Christopher Downing,
  • Jacqueline Guidry,
  • Michael Lee,
  • Stephen K. Tyring

DOI
https://doi.org/10.3390/jcm4050832
Journal volume & issue
Vol. 4, no. 5
pp. 832 – 846

Abstract

Read online

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

Keywords